Crescent Biopharma (CBIO) Leases (2020 - 2025)
Crescent Biopharma (CBIO) has disclosed Leases for 6 consecutive years, with $1.5 million as the latest value for Q4 2025.
- On a quarterly basis, Leases changed N/A to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a N/A change, with the full-year FY2025 number at $1.5 million, changed N/A from a year prior.
- Leases was $1.5 million for Q4 2025 at Crescent Biopharma, down from $1.6 million in the prior quarter.
- In the past five years, Leases ranged from a high of $2.1 million in Q1 2021 to a low of $424209.0 in Q2 2024.
- A 5-year average of $1.2 million and a median of $1.2 million in 2023 define the central range for Leases.
- Peak YoY movement for Leases: plummeted 64.13% in 2024, then surged 277.17% in 2025.
- Crescent Biopharma's Leases stood at $1.6 million in 2021, then crashed by 52.34% to $751174.0 in 2022, then rose by 2.22% to $767828.0 in 2023, then plummeted by 44.75% to $424209.0 in 2024, then surged by 246.29% to $1.5 million in 2025.
- Per Business Quant, the three most recent readings for CBIO's Leases are $1.5 million (Q4 2025), $1.6 million (Q3 2025), and $1.6 million (Q2 2025).